Core Viewpoint - The approval of BILDYOS and BILPREVDA by the European Commission marks a significant milestone for the company, enhancing its international presence and product influence in the market [1] Product Approval - BILDYOS (60mg/mL) is indicated for the treatment of osteoporosis in postmenopausal women and men at high risk of fractures, as well as for bone loss related to hormone ablation in prostate cancer patients and long-term systemic glucocorticoid treatment in adult patients at high risk of fractures [1] - BILPREVDA (120mg/1.7mL) is indicated for the prevention of skeletal-related events in adults with advanced bone malignancies and for the treatment of patients with giant cell tumors of bone that are unresectable or may lead to severe functional impairment post-surgery, including adults and skeletally mature adolescents [1] International Market Recognition - The approval in the EU follows the previous approval in the United States, representing further recognition of the company's products in major international markets, which will facilitate the company's internationalization efforts and enhance the global influence of its products [1]
复宏汉霖地舒单抗BILDYOS和BILPREVDA获欧盟批准上市